ArunKumar Namachivayam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
ArunKumar Namachivayam has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Ashwathappa Dasappa
Department of Surgical Oncology, Kidwai Memorial Institute of Oncology, Bangalore, India
2 shared publications- Joseph Mathew
Department of GI Surgical Oncology and Minimal Access Surgery, HealthCare Global Enterprises Ltd (HCG), Bangalore, India
2 shared publications Ravi Arjunan
Department of Surgical Oncology, Kidwai Memorial Institute of Oncology, Bangalore, India
2 shared publications- Abhishek Somasekhara Aradhya
Department of Pediatrics, Ovum Woman and Child Speciality hospital, Bangalore, India
1 shared publication - Akhilanand Chaurasia
Department of Oral Medicine and Radiology, King George’s Medical University, Lucknow, India
1 shared publication - Jae-Hong Lee
Department of Periodontology, College of Dentistry and Institute of Oral Bioscience, Jeonbuk National University, Jeonju, Korea; Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Korea
1 shared publication
Latest Publications
- Open Access
- 1 January 2024
- Published by XMLink in Journal of Periodontal & Implant Science
- Vol. 54 (1) , 3-12
Deep-learning performance in identifying and classifying dental implant systems from dental imaging: a systematic review and meta-analysis
Chaurasia A, et al. J Periodontal Implant Sci. 2023 Mar;53:e12. https://doi.org/10.5051/jpis.2300160008
- 1 January 2024
- Published by XMLink in Journal of Periodontal & Implant Science
- Vol. 54 (1) , 3-12
Open AccessDeep-learning performance in identifying and classifying dental implant systems from dental imaging: a systematic review and meta-analysis
Chaurasia A, et al. J Periodontal Implant Sci. 2023 Mar;53:e12. https://doi.org/10.5051/jpis.2300160008
- 25 July 2023
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30 (13) , 8673-8674
ASO Visual Abstract: Prognostic Factors and Clinical Outcomes in Extraskeletal Ewing Sarcoma—A Cohort Study
- 25 July 2023
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30 (13) , 8673-8674
ASO Visual Abstract: Prognostic Factors and Clinical Outcomes in Extraskeletal Ewing Sarcoma—A Cohort Study
- 23 December 2022
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30 (5) , 3084-3094
Prognostic Factors and Clinical Outcomes in Extraskeletal Ewing Sarcoma: A Cohort Study
Extraskeletal Ewing sarcoma (ESE) is a lesser-known, rarer counterpart of Ewing sarcoma of bone. This single-center study sought to evaluate the prognostic
- 23 December 2022
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30 (5) , 3084-3094
Prognostic Factors and Clinical Outcomes in Extraskeletal Ewing Sarcoma: A Cohort Study
Extraskeletal Ewing sarcoma (ESE) is a lesser-known, rarer counterpart of Ewing sarcoma of bone. This single-center study sought to evaluate the prognostic
- Open Access
- 1 November 2022
- Published by Pharmamedix India Publication Pvt Ltd in Asian Journal of Medical Sciences
- Vol. 13 (11) , 45-51
Current practices in organization of anesthesia drug tray
Background: The risk of medication error is high in the operating room, since the anesthesiologist prepares, stores, and administers the medication. Poor labeling practices and cluttered drug trays increase the risk of syringe swap and medication error. Well-organized drug tray can reduce the incidence of erroneous drug administration and decrease the response time during intraoperative emergencies. Aims and Objectives: The aim of the study was to determine the attitude and practices of anesthesiologists in organizing drug trays. Materials and Methods: In the first part of the study, 30 drug trays with 209 syringes were observed before and after the procedure for 14 parameters. At the end of the procedure, a questionnaire was given to the anesthesiologists involved about their knowledge of labeling and organizing drug tray. Results: All the labels were handwritten with 139 (74.7%) syringes labeled circumferentially, and 47 (25.2%) syringes labeled vertically. Unlabeled syringes found were 23 (11.0%). Labels were legible in 168 (90.3%) syringes. Syringes were not found to be replaced in their designated place according to the template at the end of surgery in 7 (23.3%) trays. About 66.7% of anesthesiologists had experienced incorrect pickup of the syringe and 40.0% of anesthesiologists reported that they rely on other pointers apart from the label to identify the drug. Conclusion: This study identifies the variation of practices in labeling, organizing, and maintaining drug tray among anesthesiologists. Adherence to institutional protocol, eternal vigilance, and improvement in error reporting practice would minimize the incidence of medication error.
- 1 November 2022
- Published by Pharmamedix India Publication Pvt Ltd in Asian Journal of Medical Sciences
- Vol. 13 (11) , 45-51
Open AccessCurrent practices in organization of anesthesia drug tray
Background: The risk of medication error is high in the operating room, since the anesthesiologist prepares, stores, and administers the medication. Poor labeling practices and cluttered drug trays increase the risk of syringe swap and medication error. Well-organized drug tray can reduce the incidence of erroneous drug administration and decrease the response time during intraoperative emergencies. Aims and Objectives: The aim of the study was to determine the attitude and practices of anesthesiologists in organizing drug trays. Materials and Methods: In the first part of the study, 30 drug trays with 209 syringes were observed before and after the procedure for 14 parameters. At the end of the procedure, a questionnaire was given to the anesthesiologists involved about their knowledge of labeling and organizing drug tray. Results: All the labels were handwritten with 139 (74.7%) syringes labeled circumferentially, and 47 (25.2%) syringes labeled vertically. Unlabeled syringes found were 23 (11.0%). Labels were legible in 168 (90.3%) syringes. Syringes were not found to be replaced in their designated place according to the template at the end of surgery in 7 (23.3%) trays. About 66.7% of anesthesiologists had experienced incorrect pickup of the syringe and 40.0% of anesthesiologists reported that they rely on other pointers apart from the label to identify the drug. Conclusion: This study identifies the variation of practices in labeling, organizing, and maintaining drug tray among anesthesiologists. Adherence to institutional protocol, eternal vigilance, and improvement in error reporting practice would minimize the incidence of medication error.
- 21 June 2022
- Published by S. Karger AG in Neonatology
- Vol. 119 (5) , 547-557
Effect of Enteral Long-Chain Polyunsaturated Fatty Acids on Retinopathy of Prematurity: A Systematic Review and Meta-Analysis
Background: Long-chain polyunsaturated fatty acids (LCPUFA) are critical for the maturation of the brain and retina. Retinopathy of prematurity (ROP) is a preventable cause of blindness in preterm infants. LCPUFA have anti-inflammatory, antioxidant, and antiangiogenesis effects. Supplementation of enteral LCPUFA might mitigate the incidence of ROP in these infants. Available limited randomized studies showed promising results. We aimed to assess the effect of enteral supplementation of LCPUFA on ROP in preterm infants. Methods: We followed PRISMA guidelines and searched MEDLINE, Cumulative Index of Nursing and Allied Health Literature, Embase, and Cochrane Registry from 1990 to 2021 for the studies that examined the effects of enteral LCPUFA and ROP in preterm infants. We included the studies that satisfied the predefined inclusion criteria. RevMan 5.3 software derived the forest plot of pooled relative risk. We assessed the quality of all the included studies using GRADE recommendations. Results: Nine studies were eligible for the meta-analysis involving 2,482 infants. Of the nine RCTs, six studies provided LCPUFA (DHA/AA) as a separate intervention in different concentrations, and three studies provided formula milk enriched with LCPUFA. In addition, five studies recruited infants below 32 weeks of gestational age. Supplementation of LCPUFA did not reduce the incidence of severe ROP (RR 0.71, 95% CI: 0.50–1.01, 5 studies, 1,822 infants) with very low CoE or any ROP (RR 0.95, 95% CI: 0.73–1.12, 6 studies, 1,177 infants) with very low CoE or ROP requiring treatment (RR 0.92, 95% CI: 0.62–1.38, 4 studies, 1,395 infants) with very low CoE. Regarding safety outcomes, enteral LCPUFA did not increase the risk of necrotizing enterocolitis or mortality. Discussion/Conclusion: Supplementation of enteral LCPUFA to preterm infants did not reduce ROP incidence; however, there was a trend toward benefit in mitigating severe form of ROP. More well-designed, large, randomized controlled studies are warranted.
- 21 June 2022
- Published by S. Karger AG in Neonatology
- Vol. 119 (5) , 547-557
Effect of Enteral Long-Chain Polyunsaturated Fatty Acids on Retinopathy of Prematurity: A Systematic Review and Meta-Analysis
Background: Long-chain polyunsaturated fatty acids (LCPUFA) are critical for the maturation of the brain and retina. Retinopathy of prematurity (ROP) is a preventable cause of blindness in preterm infants. LCPUFA have anti-inflammatory, antioxidant, and antiangiogenesis effects. Supplementation of enteral LCPUFA might mitigate the incidence of ROP in these infants. Available limited randomized studies showed promising results. We aimed to assess the effect of enteral supplementation of LCPUFA on ROP in preterm infants. Methods: We followed PRISMA guidelines and searched MEDLINE, Cumulative Index of Nursing and Allied Health Literature, Embase, and Cochrane Registry from 1990 to 2021 for the studies that examined the effects of enteral LCPUFA and ROP in preterm infants. We included the studies that satisfied the predefined inclusion criteria. RevMan 5.3 software derived the forest plot of pooled relative risk. We assessed the quality of all the included studies using GRADE recommendations. Results: Nine studies were eligible for the meta-analysis involving 2,482 infants. Of the nine RCTs, six studies provided LCPUFA (DHA/AA) as a separate intervention in different concentrations, and three studies provided formula milk enriched with LCPUFA. In addition, five studies recruited infants below 32 weeks of gestational age. Supplementation of LCPUFA did not reduce the incidence of severe ROP (RR 0.71, 95% CI: 0.50–1.01, 5 studies, 1,822 infants) with very low CoE or any ROP (RR 0.95, 95% CI: 0.73–1.12, 6 studies, 1,177 infants) with very low CoE or ROP requiring treatment (RR 0.92, 95% CI: 0.62–1.38, 4 studies, 1,395 infants) with very low CoE. Regarding safety outcomes, enteral LCPUFA did not increase the risk of necrotizing enterocolitis or mortality. Discussion/Conclusion: Supplementation of enteral LCPUFA to preterm infants did not reduce ROP incidence; however, there was a trend toward benefit in mitigating severe form of ROP. More well-designed, large, randomized controlled studies are warranted.
- Open Access
- 1 April 2021
- Published by Jaypee Brothers Medical Publishing in Indian Journal of Critical Care Medicine
- Vol. 25 (4) , 441-452
Evidence for Chloroquine/Hydroxychloroquine in the Treatment of COVID-19
Introduction: Given the current lack of an approved and effective treatment or vaccine for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), repositioning old drugs for use as an antiviral treatment is an interesting strategy because knowledge about these drugs' safety profile, posology, and drug interactions is already known. Chloroquine and hydroxychloroquine, widely used as antimalarial and autoimmune disease drugs, have recently been reported as a potential broad-spectrum antiviral drug. Background: The in vitro antiviral activity of chloroquine has been identified since the late 1960s. However, antiviral mechanisms of chloroquine remain speculative. Several clinical trials have been conducted to test the efficacy and safety of chioroquine or hydroxychloroquine in the treatment of COVID-19-associated pneumonia. The quality of the studies and the outcomes are evaluated in this systematic review and meta-analysis. Review results: Literature review revealed 23 clinical studies. On& 9 of 23 studies were randomized controlled trials. Of nine randomized controlled trials, only study by Skipper et al. was deemed to be at low risk of bias. All studies evaluated variedwith different outcomes. Mechanical ventilation and virological clearance were the only common outcomes evaluated in more than two studies. Virological clearance odds ratio (OR) was 1.25 (95% confidence interval [CI] of 0.57-2.73; Chi(2) = 0.83; I-2 = 0%). GRADE quality of evidence was downgraded by three levels to very low due to concerns about the risk of bias, inconsistency, and imprecision. For mechanical ventilation, OR was 1.09 (95% CI 0.80-1.50; Chi(2) =0; I-2 = 0). GRADE quality of evidence was downgraded by two levels to low due to concerns about the risk of bias and imprecision. There was no statistically significant difference between the groups for these two outcomes. Conclusion: As per the available evidence, based on our review, we conclude that hydroxychloroquine/chloroquine has not shown to be beneficial when used for the treatment of patients with COVID-19 pneumonia.
- 1 April 2021
- Published by Jaypee Brothers Medical Publishing in Indian Journal of Critical Care Medicine
- Vol. 25 (4) , 441-452
Open AccessEvidence for Chloroquine/Hydroxychloroquine in the Treatment of COVID-19
Introduction: Given the current lack of an approved and effective treatment or vaccine for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), repositioning old drugs for use as an antiviral treatment is an interesting strategy because knowledge about these drugs' safety profile, posology, and drug interactions is already known. Chloroquine and hydroxychloroquine, widely used as antimalarial and autoimmune disease drugs, have recently been reported as a potential broad-spectrum antiviral drug. Background: The in vitro antiviral activity of chloroquine has been identified since the late 1960s. However, antiviral mechanisms of chloroquine remain speculative. Several clinical trials have been conducted to test the efficacy and safety of chioroquine or hydroxychloroquine in the treatment of COVID-19-associated pneumonia. The quality of the studies and the outcomes are evaluated in this systematic review and meta-analysis. Review results: Literature review revealed 23 clinical studies. On& 9 of 23 studies were randomized controlled trials. Of nine randomized controlled trials, only study by Skipper et al. was deemed to be at low risk of bias. All studies evaluated variedwith different outcomes. Mechanical ventilation and virological clearance were the only common outcomes evaluated in more than two studies. Virological clearance odds ratio (OR) was 1.25 (95% confidence interval [CI] of 0.57-2.73; Chi(2) = 0.83; I-2 = 0%). GRADE quality of evidence was downgraded by three levels to very low due to concerns about the risk of bias, inconsistency, and imprecision. For mechanical ventilation, OR was 1.09 (95% CI 0.80-1.50; Chi(2) =0; I-2 = 0). GRADE quality of evidence was downgraded by two levels to low due to concerns about the risk of bias and imprecision. There was no statistically significant difference between the groups for these two outcomes. Conclusion: As per the available evidence, based on our review, we conclude that hydroxychloroquine/chloroquine has not shown to be beneficial when used for the treatment of patients with COVID-19 pneumonia.